 Cara Wilson
Concepts (308)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV-1 | 35 | 2026 | 895 | 4.540 |
Why?
| | HIV Infections | 48 | 2026 | 3079 | 3.980 |
Why?
| | CD4-Positive T-Lymphocytes | 23 | 2026 | 1128 | 3.350 |
Why?
| | Intestinal Mucosa | 11 | 2021 | 676 | 3.270 |
Why?
| | Dysbiosis | 8 | 2022 | 187 | 2.150 |
Why?
| | Gastrointestinal Microbiome | 11 | 2024 | 771 | 2.140 |
Why?
| | Immunity, Mucosal | 5 | 2017 | 98 | 1.730 |
Why?
| | Dendritic Cells | 12 | 2020 | 499 | 1.670 |
Why?
| | Lymphocyte Activation | 13 | 2017 | 1126 | 1.470 |
Why?
| | Bacterial Translocation | 6 | 2019 | 52 | 1.370 |
Why?
| | Interferon-gamma | 10 | 2019 | 784 | 1.340 |
Why?
| | Colon | 5 | 2024 | 304 | 1.280 |
Why?
| | Lymphocytes | 3 | 2021 | 382 | 1.240 |
Why?
| | Gastrointestinal Tract | 5 | 2022 | 208 | 1.230 |
Why?
| | Epitopes, T-Lymphocyte | 8 | 2010 | 175 | 1.170 |
Why?
| | Butyrates | 2 | 2021 | 67 | 1.130 |
Why?
| | Viremia | 6 | 2016 | 158 | 1.110 |
Why?
| | Salmonella typhimurium | 2 | 2021 | 190 | 0.960 |
Why?
| | Immunity, Innate | 4 | 2021 | 846 | 0.950 |
Why?
| | T-Lymphocytes, Cytotoxic | 5 | 2026 | 177 | 0.890 |
Why?
| | Escherichia coli | 3 | 2014 | 852 | 0.880 |
Why?
| | AIDS Vaccines | 5 | 2016 | 52 | 0.870 |
Why?
| | Th1 Cells | 2 | 2019 | 139 | 0.850 |
Why?
| | Granzymes | 2 | 2022 | 49 | 0.850 |
Why?
| | Bacteria | 4 | 2022 | 889 | 0.760 |
Why?
| | Viral Load | 11 | 2016 | 518 | 0.740 |
Why?
| | Interleukin-23 | 2 | 2013 | 16 | 0.720 |
Why?
| | Escherichia coli Infections | 2 | 2013 | 129 | 0.720 |
Why?
| | Ruminococcus | 1 | 2021 | 8 | 0.690 |
Why?
| | Acinetobacter | 1 | 2021 | 15 | 0.690 |
Why?
| | Interleukin-15 | 1 | 2021 | 97 | 0.660 |
Why?
| | Microbiota | 5 | 2023 | 781 | 0.640 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2021 | 220 | 0.610 |
Why?
| | HIV Core Protein p24 | 5 | 2006 | 32 | 0.600 |
Why?
| | Vaccines, DNA | 3 | 2016 | 31 | 0.600 |
Why?
| | Pyrrolidinones | 3 | 2014 | 29 | 0.580 |
Why?
| | Gram-Positive Bacteria | 1 | 2019 | 47 | 0.580 |
Why?
| | Immunologic Factors | 2 | 2018 | 255 | 0.570 |
Why?
| | Th17 Cells | 1 | 2019 | 100 | 0.570 |
Why?
| | Gram-Negative Bacteria | 1 | 2019 | 81 | 0.570 |
Why?
| | T-Lymphocytes | 8 | 2021 | 1982 | 0.560 |
Why?
| | Gene Products, gag | 5 | 2007 | 38 | 0.530 |
Why?
| | Interleukins | 1 | 2019 | 248 | 0.520 |
Why?
| | Interferon Type I | 1 | 2018 | 145 | 0.520 |
Why?
| | Inflammation | 9 | 2021 | 2877 | 0.510 |
Why?
| | Receptors, IgG | 2 | 2014 | 76 | 0.500 |
Why?
| | Aging | 2 | 2020 | 1964 | 0.480 |
Why?
| | Ritonavir | 2 | 2013 | 75 | 0.460 |
Why?
| | Humans | 66 | 2026 | 144261 | 0.430 |
Why?
| | Anti-HIV Agents | 5 | 2014 | 869 | 0.410 |
Why?
| | Enterobacteriaceae | 2 | 2017 | 43 | 0.410 |
Why?
| | HIV Antigens | 3 | 2016 | 17 | 0.410 |
Why?
| | Lymphocyte Subsets | 1 | 2014 | 83 | 0.410 |
Why?
| | Cells, Cultured | 9 | 2021 | 4146 | 0.400 |
Why?
| | Flow Cytometry | 7 | 2017 | 1172 | 0.400 |
Why?
| | Apoptosis | 2 | 2014 | 2430 | 0.400 |
Why?
| | Antiretroviral Therapy, Highly Active | 5 | 2014 | 277 | 0.390 |
Why?
| | Adult | 30 | 2024 | 40262 | 0.390 |
Why?
| | Young Adult | 17 | 2020 | 13990 | 0.380 |
Why?
| | Interferon-alpha | 3 | 2020 | 197 | 0.370 |
Why?
| | Virus Replication | 5 | 2016 | 529 | 0.360 |
Why?
| | Sulfonamides | 2 | 2013 | 580 | 0.360 |
Why?
| | Movement | 1 | 2014 | 293 | 0.360 |
Why?
| | Middle Aged | 28 | 2024 | 35762 | 0.350 |
Why?
| | Killer Cells, Natural | 2 | 2016 | 467 | 0.350 |
Why?
| | CD8-Positive T-Lymphocytes | 7 | 2016 | 917 | 0.340 |
Why?
| | Immunophenotyping | 6 | 2014 | 322 | 0.340 |
Why?
| | Monocytes | 1 | 2013 | 538 | 0.330 |
Why?
| | Toll-Like Receptor 8 | 1 | 2010 | 8 | 0.320 |
Why?
| | Toll-Like Receptor 7 | 1 | 2010 | 43 | 0.310 |
Why?
| | Caspase 3 | 1 | 2010 | 238 | 0.310 |
Why?
| | Interleukin-2 | 4 | 2022 | 437 | 0.300 |
Why?
| | Myeloid Cells | 1 | 2010 | 148 | 0.300 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2010 | 240 | 0.300 |
Why?
| | Cytokines | 8 | 2018 | 2061 | 0.290 |
Why?
| | CD4 Lymphocyte Count | 6 | 2014 | 274 | 0.290 |
Why?
| | RNA, Viral | 5 | 2014 | 687 | 0.280 |
Why?
| | Interleukin-17 | 3 | 2023 | 118 | 0.280 |
Why?
| | Lymphoid Tissue | 1 | 2008 | 80 | 0.270 |
Why?
| | Phenotype | 5 | 2019 | 3157 | 0.260 |
Why?
| | Antiviral Agents | 3 | 2020 | 767 | 0.260 |
Why?
| | Leukocytes, Mononuclear | 4 | 2024 | 573 | 0.250 |
Why?
| | Cross-Sectional Studies | 5 | 2018 | 5813 | 0.250 |
Why?
| | Male | 28 | 2024 | 72035 | 0.250 |
Why?
| | Cell Proliferation | 7 | 2021 | 2494 | 0.240 |
Why?
| | Conserved Sequence | 2 | 2003 | 245 | 0.240 |
Why?
| | CD57 Antigens | 1 | 2005 | 18 | 0.240 |
Why?
| | Interleukin-10 | 2 | 2021 | 309 | 0.230 |
Why?
| | GPI-Linked Proteins | 3 | 2016 | 80 | 0.230 |
Why?
| | Case-Control Studies | 9 | 2022 | 3592 | 0.230 |
Why?
| | Lipopolysaccharide Receptors | 3 | 2021 | 87 | 0.210 |
Why?
| | Biomarkers | 7 | 2021 | 4254 | 0.210 |
Why?
| | Female | 23 | 2024 | 77976 | 0.210 |
Why?
| | Cytotoxicity Tests, Immunologic | 1 | 2003 | 37 | 0.210 |
Why?
| | Receptors, Antigen, T-Cell | 3 | 2021 | 668 | 0.200 |
Why?
| | Endogenous Retroviruses | 1 | 2024 | 38 | 0.200 |
Why?
| | Viral Proteins | 1 | 2006 | 355 | 0.190 |
Why?
| | Chloroquine | 2 | 2016 | 53 | 0.190 |
Why?
| | Aged | 12 | 2021 | 25850 | 0.190 |
Why?
| | Somatic Hypermutation, Immunoglobulin | 1 | 2022 | 19 | 0.190 |
Why?
| | Arthritis, Experimental | 1 | 2023 | 141 | 0.180 |
Why?
| | Gene Expression Profiling | 5 | 2024 | 1782 | 0.180 |
Why?
| | Yeasts | 1 | 2002 | 52 | 0.180 |
Why?
| | Blood | 1 | 2022 | 109 | 0.170 |
Why?
| | Vaccines, Synthetic | 1 | 2002 | 138 | 0.170 |
Why?
| | Saccharomyces cerevisiae | 1 | 2006 | 578 | 0.170 |
Why?
| | Propionates | 1 | 2021 | 39 | 0.170 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 2002 | 231 | 0.170 |
Why?
| | Acetates | 1 | 2021 | 80 | 0.170 |
Why?
| | Immunoglobulin A | 1 | 2022 | 214 | 0.170 |
Why?
| | Interferons | 1 | 2022 | 188 | 0.160 |
Why?
| | Acetylation | 1 | 2021 | 252 | 0.160 |
Why?
| | Genetic Vectors | 1 | 2002 | 337 | 0.160 |
Why?
| | Interferon-beta | 1 | 2020 | 92 | 0.160 |
Why?
| | Bacteria, Anaerobic | 1 | 2020 | 25 | 0.160 |
Why?
| | Immunity, Humoral | 2 | 2022 | 120 | 0.150 |
Why?
| | Immunologic Memory | 3 | 2009 | 366 | 0.150 |
Why?
| | Immune Tolerance | 2 | 2014 | 379 | 0.150 |
Why?
| | Adaptive Immunity | 1 | 2021 | 169 | 0.150 |
Why?
| | Shoulder | 1 | 2020 | 105 | 0.150 |
Why?
| | Receptors, Cell Surface | 1 | 2021 | 377 | 0.150 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2021 | 233 | 0.150 |
Why?
| | Raltegravir Potassium | 3 | 2014 | 18 | 0.150 |
Why?
| | Simian Acquired Immunodeficiency Syndrome | 1 | 2019 | 92 | 0.150 |
Why?
| | Lymphocyte Depletion | 2 | 2012 | 132 | 0.140 |
Why?
| | Phylogeny | 2 | 2017 | 1015 | 0.140 |
Why?
| | Diet, High-Fat | 1 | 2019 | 261 | 0.140 |
Why?
| | T-Cell Antigen Receptor Specificity | 3 | 2006 | 45 | 0.140 |
Why?
| | Microbial Interactions | 1 | 2017 | 19 | 0.130 |
Why?
| | Transcriptome | 2 | 2022 | 1044 | 0.130 |
Why?
| | Feces | 2 | 2019 | 513 | 0.130 |
Why?
| | Proteome | 1 | 2022 | 514 | 0.130 |
Why?
| | Antigens, CD | 4 | 2016 | 555 | 0.130 |
Why?
| | Interleukin-1beta | 1 | 2019 | 395 | 0.130 |
Why?
| | DNA, Ribosomal | 1 | 2017 | 94 | 0.130 |
Why?
| | Cell Differentiation | 3 | 2011 | 2048 | 0.120 |
Why?
| | Chronic Disease | 5 | 2010 | 1812 | 0.120 |
Why?
| | Darunavir | 2 | 2013 | 20 | 0.120 |
Why?
| | Anti-Retroviral Agents | 1 | 2018 | 240 | 0.120 |
Why?
| | Fungi | 1 | 2017 | 161 | 0.120 |
Why?
| | Histones | 1 | 2021 | 668 | 0.120 |
Why?
| | Interleukin-12 | 1 | 2016 | 117 | 0.110 |
Why?
| | DNA, Bacterial | 1 | 2017 | 342 | 0.110 |
Why?
| | Cluster Analysis | 1 | 2017 | 519 | 0.110 |
Why?
| | Age Factors | 2 | 2019 | 3313 | 0.110 |
Why?
| | In Vitro Techniques | 2 | 2014 | 1047 | 0.110 |
Why?
| | Biopsy | 1 | 2018 | 1075 | 0.110 |
Why?
| | Rifamycins | 1 | 2014 | 6 | 0.110 |
Why?
| | Colitis | 1 | 2017 | 280 | 0.110 |
Why?
| | Arthritis, Rheumatoid | 1 | 2023 | 1168 | 0.110 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2017 | 558 | 0.110 |
Why?
| | T-Lymphocyte Subsets | 3 | 2007 | 415 | 0.110 |
Why?
| | Immunity, Cellular | 1 | 2016 | 272 | 0.100 |
Why?
| | HLA-DR Antigens | 3 | 2008 | 220 | 0.100 |
Why?
| | Thromboplastin | 1 | 2014 | 69 | 0.100 |
Why?
| | Polyamines | 1 | 2014 | 42 | 0.100 |
Why?
| | CD56 Antigen | 1 | 2014 | 35 | 0.100 |
Why?
| | Lipoproteins, LDL | 1 | 2014 | 114 | 0.100 |
Why?
| | Physical Fitness | 1 | 2015 | 209 | 0.100 |
Why?
| | Sequence Analysis, DNA | 1 | 2017 | 824 | 0.100 |
Why?
| | Amino Acid Sequence | 3 | 2006 | 2154 | 0.100 |
Why?
| | Intestines | 1 | 2017 | 358 | 0.100 |
Why?
| | Caspase 1 | 1 | 2014 | 148 | 0.100 |
Why?
| | Cytomegalovirus Infections | 1 | 2015 | 206 | 0.100 |
Why?
| | Mucous Membrane | 1 | 2014 | 127 | 0.100 |
Why?
| | Melanoma | 2 | 2011 | 760 | 0.100 |
Why?
| | Aged, 80 and over | 3 | 2021 | 8243 | 0.100 |
Why?
| | Homeostasis | 1 | 2017 | 640 | 0.090 |
Why?
| | Cardiovascular Agents | 1 | 2014 | 163 | 0.090 |
Why?
| | Adolescent | 6 | 2019 | 22281 | 0.090 |
Why?
| | Cholesterol, LDL | 1 | 2014 | 353 | 0.090 |
Why?
| | Blood Coagulation | 1 | 2014 | 268 | 0.090 |
Why?
| | Pilot Projects | 1 | 2017 | 1867 | 0.090 |
Why?
| | Suppressor Factors, Immunologic | 1 | 2011 | 4 | 0.090 |
Why?
| | Molecular Sequence Data | 2 | 2006 | 2929 | 0.090 |
Why?
| | HIV Seropositivity | 2 | 2019 | 118 | 0.090 |
Why?
| | Toll-Like Receptor 4 | 1 | 2013 | 276 | 0.090 |
Why?
| | Antibodies, Viral | 1 | 2015 | 672 | 0.080 |
Why?
| | Genes, bcl-2 | 1 | 2010 | 22 | 0.080 |
Why?
| | Gene Expression Regulation | 2 | 2024 | 2603 | 0.080 |
Why?
| | Cell Survival | 1 | 2014 | 1098 | 0.080 |
Why?
| | Motor Activity | 1 | 2015 | 720 | 0.080 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2014 | 549 | 0.080 |
Why?
| | Antigens, CD1 | 1 | 2010 | 60 | 0.080 |
Why?
| | Disease Progression | 3 | 2019 | 2840 | 0.080 |
Why?
| | Cytomegalovirus | 2 | 2015 | 168 | 0.070 |
Why?
| | Cell Separation | 1 | 2010 | 307 | 0.070 |
Why?
| | Signal Transduction | 2 | 2021 | 5221 | 0.070 |
Why?
| | Exercise | 1 | 2021 | 2193 | 0.070 |
Why?
| | Reference Standards | 1 | 2009 | 177 | 0.070 |
Why?
| | Double-Blind Method | 2 | 2016 | 2025 | 0.070 |
Why?
| | Sequence Alignment | 2 | 2006 | 366 | 0.070 |
Why?
| | Glycoproteins | 1 | 2010 | 355 | 0.070 |
Why?
| | HLA-A3 Antigen | 2 | 2004 | 6 | 0.070 |
Why?
| | Mice, Transgenic | 3 | 2016 | 2182 | 0.060 |
Why?
| | HLA-A2 Antigen | 2 | 2004 | 35 | 0.060 |
Why?
| | DNA Primers | 1 | 2008 | 511 | 0.060 |
Why?
| | Fluorides | 1 | 2006 | 49 | 0.060 |
Why?
| | Polyurethanes | 1 | 2006 | 38 | 0.060 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2007 | 186 | 0.060 |
Why?
| | Lymphocyte Culture Test, Mixed | 1 | 2006 | 51 | 0.060 |
Why?
| | gag Gene Products, Human Immunodeficiency Virus | 1 | 2006 | 10 | 0.060 |
Why?
| | Anti-Infective Agents | 1 | 2009 | 242 | 0.060 |
Why?
| | Methacrylates | 1 | 2006 | 119 | 0.060 |
Why?
| | HIV | 1 | 2007 | 248 | 0.060 |
Why?
| | Membrane Glycoproteins | 2 | 2013 | 496 | 0.060 |
Why?
| | Receptors, CCR7 | 1 | 2005 | 31 | 0.060 |
Why?
| | Receptors, Chemokine | 1 | 2005 | 47 | 0.060 |
Why?
| | Leukocyte Common Antigens | 1 | 2005 | 88 | 0.060 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2008 | 850 | 0.060 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2008 | 388 | 0.060 |
Why?
| | Recombination, Genetic | 1 | 2006 | 205 | 0.060 |
Why?
| | Antigenic Variation | 1 | 2004 | 11 | 0.050 |
Why?
| | Base Sequence | 1 | 2008 | 2187 | 0.050 |
Why?
| | Beryllium | 1 | 2005 | 161 | 0.050 |
Why?
| | HLA-B7 Antigen | 1 | 2003 | 7 | 0.050 |
Why?
| | Long Interspersed Nucleotide Elements | 1 | 2024 | 32 | 0.050 |
Why?
| | Retroelements | 1 | 2024 | 51 | 0.050 |
Why?
| | Superantigens | 1 | 2003 | 70 | 0.050 |
Why?
| | Anti-Bacterial Agents | 1 | 2014 | 1906 | 0.050 |
Why?
| | Histocompatibility Testing | 1 | 2003 | 121 | 0.050 |
Why?
| | Cell Line, Transformed | 1 | 2003 | 140 | 0.050 |
Why?
| | Amino Acid Motifs | 1 | 2003 | 224 | 0.050 |
Why?
| | Berylliosis | 1 | 2005 | 202 | 0.050 |
Why?
| | B7-2 Antigen | 1 | 2002 | 27 | 0.050 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2003 | 194 | 0.050 |
Why?
| | Longitudinal Studies | 2 | 2018 | 2926 | 0.050 |
Why?
| | Animals | 6 | 2023 | 38030 | 0.050 |
Why?
| | Receptors, CCR5 | 1 | 2002 | 60 | 0.050 |
Why?
| | Mutation | 1 | 2014 | 4085 | 0.050 |
Why?
| | Clone Cells | 1 | 2003 | 266 | 0.050 |
Why?
| | Receptors, CXCR4 | 1 | 2002 | 91 | 0.050 |
Why?
| | Tryptophan | 1 | 2023 | 180 | 0.050 |
Why?
| | HLA-DRB1 Chains | 1 | 2003 | 109 | 0.050 |
Why?
| | Cell Division | 1 | 2004 | 766 | 0.050 |
Why?
| | T-Lymphocytes, Helper-Inducer | 1 | 2003 | 131 | 0.050 |
Why?
| | Epitopes | 1 | 2004 | 485 | 0.050 |
Why?
| | CD40 Antigens | 1 | 2002 | 90 | 0.050 |
Why?
| | Datasets as Topic | 1 | 2022 | 122 | 0.040 |
Why?
| | Receptors, Tumor Necrosis Factor, Type II | 1 | 2021 | 41 | 0.040 |
Why?
| | Mice | 4 | 2023 | 18329 | 0.040 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2003 | 364 | 0.040 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 2003 | 331 | 0.040 |
Why?
| | Collagen | 1 | 2023 | 455 | 0.040 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 1 | 2021 | 81 | 0.040 |
Why?
| | Lipopolysaccharides | 2 | 2014 | 863 | 0.040 |
Why?
| | Genetic Variation | 1 | 2006 | 982 | 0.040 |
Why?
| | Alleles | 1 | 2003 | 878 | 0.040 |
Why?
| | Fatty Acids, Volatile | 1 | 2019 | 60 | 0.040 |
Why?
| | Predictive Value of Tests | 1 | 2003 | 2111 | 0.030 |
Why?
| | Cohort Studies | 2 | 2010 | 5935 | 0.030 |
Why?
| | Metagenome | 1 | 2019 | 149 | 0.030 |
Why?
| | Inpatients | 1 | 2022 | 542 | 0.030 |
Why?
| | Metagenomics | 1 | 2019 | 181 | 0.030 |
Why?
| | Body Composition | 1 | 2021 | 704 | 0.030 |
Why?
| | Symbiosis | 1 | 2017 | 81 | 0.030 |
Why?
| | Interleukin-6 | 1 | 2021 | 780 | 0.030 |
Why?
| | APOBEC-3G Deaminase | 1 | 2016 | 5 | 0.030 |
Why?
| | Bone Marrow Stromal Antigen 2 | 1 | 2016 | 11 | 0.030 |
Why?
| | Myxovirus Resistance Proteins | 1 | 2016 | 13 | 0.030 |
Why?
| | Protein Binding | 1 | 2003 | 2270 | 0.030 |
Why?
| | Bacterial Infections | 1 | 2018 | 246 | 0.030 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2021 | 1217 | 0.030 |
Why?
| | Placebos | 1 | 2016 | 192 | 0.030 |
Why?
| | Electroporation | 1 | 2016 | 41 | 0.030 |
Why?
| | Adipose Tissue | 1 | 2019 | 651 | 0.030 |
Why?
| | Cardiovascular Diseases | 2 | 2019 | 2134 | 0.030 |
Why?
| | Virion | 1 | 2015 | 111 | 0.030 |
Why?
| | Sevelamer | 1 | 2014 | 9 | 0.030 |
Why?
| | Treatment Outcome | 3 | 2014 | 11643 | 0.030 |
Why?
| | Computational Biology | 1 | 2019 | 680 | 0.030 |
Why?
| | Cross-Over Studies | 1 | 2016 | 600 | 0.030 |
Why?
| | ADP-ribosyl Cyclase 1 | 1 | 2013 | 43 | 0.020 |
Why?
| | Drug Resistance, Viral | 1 | 2014 | 122 | 0.020 |
Why?
| | Treatment Failure | 1 | 2014 | 363 | 0.020 |
Why?
| | Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2011 | 55 | 0.020 |
Why?
| | Prospective Studies | 1 | 2004 | 7970 | 0.020 |
Why?
| | Culture Media, Conditioned | 1 | 2011 | 111 | 0.020 |
Why?
| | Diet | 1 | 2019 | 1271 | 0.020 |
Why?
| | Liver | 1 | 2019 | 1884 | 0.020 |
Why?
| | Immunoglobulin G | 1 | 2015 | 893 | 0.020 |
Why?
| | Endocytosis | 1 | 2011 | 168 | 0.020 |
Why?
| | Myocardial Infarction | 1 | 2018 | 1208 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2011 | 778 | 0.020 |
Why?
| | Stroke | 1 | 2018 | 1254 | 0.020 |
Why?
| | Odds Ratio | 1 | 2011 | 1072 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2011 | 1044 | 0.020 |
Why?
| | Lymphocyte Count | 1 | 2008 | 164 | 0.020 |
Why?
| | Drug Monitoring | 1 | 2011 | 389 | 0.020 |
Why?
| | Antibodies, Blocking | 1 | 2007 | 37 | 0.020 |
Why?
| | Transforming Growth Factor beta | 1 | 2008 | 479 | 0.010 |
Why?
| | Ligands | 1 | 2007 | 673 | 0.010 |
Why?
| | Selection Bias | 1 | 2005 | 38 | 0.010 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2007 | 264 | 0.010 |
Why?
| | B7-H1 Antigen | 1 | 2007 | 241 | 0.010 |
Why?
| | Gene Products, env | 1 | 2004 | 7 | 0.010 |
Why?
| | Gene Products, pol | 1 | 2004 | 6 | 0.010 |
Why?
| | Lymph Nodes | 1 | 2007 | 502 | 0.010 |
Why?
| | Genes, MHC Class I | 1 | 2004 | 36 | 0.010 |
Why?
| | Survivors | 1 | 2008 | 516 | 0.010 |
Why?
| | Up-Regulation | 1 | 2007 | 851 | 0.010 |
Why?
| | Amino Acid Substitution | 1 | 2004 | 304 | 0.010 |
Why?
| | Survival Rate | 1 | 2008 | 2088 | 0.010 |
Why?
| | Neoplasms | 1 | 2018 | 2870 | 0.010 |
Why?
| | Peptide Fragments | 1 | 2004 | 698 | 0.010 |
Why?
| | Research Design | 1 | 2005 | 1129 | 0.010 |
Why?
| | Algorithms | 1 | 2004 | 1834 | 0.010 |
Why?
| | Lung | 1 | 2005 | 4108 | 0.010 |
Why?
|
|
Wilson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|